

This newsletter summarises final decisions from HTA bodies around the world from June 2023.

These decisions have been categorised into one of four groups. You can click on the category you are interested in to jump to that section.

[Pharmacological Technologies](#)

[Non-pharmacological Technologies](#)

[Diagnostic Tests](#)

[Other Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter.



Approved - This is where the reporting document states that the technology has been approved.



Not approved - This is where the reporting document states that the technology has not been approved.



Terminated - The report was terminated, additional details are provided under the icon.



Excluded - The report was excluded because it is covered by another HTA body in that country.



Unclear - This is where documentation cannot be translated or it is unclear on the reporting outcome.



Note - This entry includes a note from the report relating to the technology.



Evidence review - This is for reports that do not report a decision but summarises the evidence for the technology.

Pharmacological Technologies



Blood


- Emicizumab - France
- Etranacogen dezaparvovec - France
- Voxelotor - France
- Emicizumab - Germany



Cancer

- Nivolumab - Scotland
- Treosulfan - Scotland
- Polatuzumab vedotin - Scotland
- Pembrolizumab - Scotland
- Tebentafusp - France
- Tabelecleucel - France
- Zanubrutinib - France
- Venetoclax - France
- Temozolomide - France
- Amivantamab - France
- Burosumab - France
- Avapritinib - France
- Zanubrutinib - Germany
- Zanubrutinib - Germany
- Rituximab - Brazil
- Daratumumab with bortezomib and dexamethasone - England
- Axicabtagene ciloleucel - England
- Axicabtagene ciloleucel - England
- Brexucabtagene autoleucel - England
- Dabrafenib plus trametinib - England
- Cemiplimab - England
- Pembrolizumab with lenvatinib - England

- Darolutamide with androgen deprivation therapy and docetaxel - England
- Cemiplimab - Wales
- Dapagliflozin - Germany
- Rituximab - Brazil
- Direct oral anticoagulants - Switzerland
- Dapagliflozin - England
- Mavacamten - Wales
- Metreleptin - Scotland
- Liraglutide - Brazil




Cardiovascular



Endocrine



Eye



Gastrointestinal



Genitourinary

- Inebilizumab - France
- Latanoprost/netarsudil - Germany
- Latanoprost/netarsudil - Germany
- Upadacitinib - Scotland
- Risankizumab - Germany
- Risankizumab - Germany
- Bulevirtide - England
- Upadacitinib - England
- Upadacitinib - Wales
- Voclosporin - Germany
- Finerenone - Germany
- Finerenone - Germany
- Botulinum toxin type A - England

Pharmacological Technologies



Infection

- Tixagevimab and cilgavimab - Scotland
- Dolutegravir/abacavir/lamivudine - Germany
- Tixagevimab plus cilgavimab - England
- Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab - England




Mental Health

- Esketamine - Germany
- Esketamine - England




Metabolic /Genetic

- Evinacumab - France



Musculoskeletal

- Alternative therapies to Immunoglobulin - Canada



Skin

- Deucravacitinib - England
- Deucravacitinib - Wales

Other


- Olopatadine/mometasone - Germany

Non-pharmacological Technologies




Cancer

- Photodynamic therapy - Brazil



Gastrointestinal

- Endoscopic ultrasound - England



Musculoskeletal

- Minimally invasive fusionless posterior-approach surgery - England
- Radiofrequency denervation - England
- Deep brain stimulation - Canada



Neurology

- Telemonitoring of lung function - Spain



Respiratory

Diagnostic Tests




Blood

- [Folic acid test - Switzerland](#)




Cancer

- [Transperineal biopsy - England](#)



Cardiovascular

- [Computer tomography coronary angiography - Germany](#)



Gastrointestinal

- [FibroScan - England](#)



Infection

- [Nucleotide amplification in blood - Spain](#)

Other Guidance



Cancer

- [Tisagenlecleucel/axicabtagene ciloleucel - Switzerland](#)
- [177Lu-PSMA-617 - Norway](#)
- [Intraoperative electron beam radiotherapy - England](#)




Neurology

- [Domiciliary invasive ventilation - Ireland](#)



Pregnancy

- [Postpartum care - United States](#)



Skin

- [Antimicrobial or antiseptic cleansers - Canada](#)

Pharmacological Technologies



Blood


<p>France</p>  <p>Emicizumab</p> <p>Population: Other All age groups</p> <p>01 June 2023</p>	<p>Prophylaxis to prevent bleeding episodes in patients with haemophilia A.</p> <p><i>HAS AP-198</i></p> <p></p>	<p>France</p>  <p>Etranacogen dezaparvovec</p> <p>Population: Adult</p> <p>01 June 2023</p>	<p>Treatment of severe and moderately severe haemophilia B in patients without factor IX inhibitors.</p> <p><i>HAS AP-194</i></p> <p></p>
<p>France</p>  <p>Voxelotor</p> <p>Population: Other Adult and adolescents, over 12 years</p> <p>21 June 2023</p>	<p>Treatment of severe haemolytic anemia caused by sickle cell disease.</p> <p><i>HAS AP-206</i></p> <p></p>	<p>Germany</p>  <p>Emicizumab</p> <p>Population: Other All age groups</p> <p>01 June 2023</p>	<p>Routine prophylaxis of bleeding episodes for patients with haemophilia A.</p> <p><i>IQWiG A23-10</i></p> <p></p>

Pharmacological Technologies



Cancer


Scotland



Nivolumab

Population:
Adult

12 June 2023



Combination therapy for first-line treatment in oesophageal cancer.

SMC2519



Accepted for restricted use


Scotland



Treosulfan

Population:
Children
Paediatrics over 1 month

12 June 2023




Combination therapy with fludarabine as part of conditioning for allogenic haematopoietic stem cell transplantation.

SMC2527



Accepted for restricted use


Scotland



Polatuzumab vedotin


Population:
Adult

12 June 2023




Combination therapy for untreated diffuse large B-cell lymphoma.

SMC2525



Accepted for restricted use

Scotland



Pembrolizumab

Population:
Adult

12 June 2023



Combination with chemotherapy then continued as monotherapy after surgery for breast cancer.

SMC2538



Accepted for restricted use

Pharmacological Technologies



Cancer


France



Tebentafusp

Population:
Adult

01 June 2023



Treatment of uveal melanoma in patients positive for human leukocyte antigen.

HAS AP-184




France



Tabelecleucel

Population:
Other Adults and Children, above 2 years

16 June 2023



Treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease

HAS AP-199




France



Zanubrutinib

Population:
Adult

16 June 2023



Monotherapy for the treatment of marginal zone lymphoma.

HAS AP-205




France



Venetoclax


Population:
Adult

21 June 2023



Combination therapy with obinutuzumab for patients with chronic lymphocytic leukaemia.

HAS AP-213



Pharmacological Technologies



Cancer

France



Temozolomide

Population:
Children
Age 1 to 6 years and
above 6 year for
those unable to
swallow capsules
21 June 2023

Monotherapy or
combination therapy for
the treatment of patients
with neuroblastoma.

HAS AP-203



APPROVED

France




Amivantamab

Population:
Adult
22 June 2023

Monotherapy for
patients suffering for
non-small cell lung
cancer.

HAS AP-191



APPROVED

Orphan drug status

France



Burosumab

Population:
Other
Adults and Children,
above 1 year
30 June 2023


Treatment of
hypophosphatemia in
patients with oncogenic
osteomalacia
associated with
phosphaturic
mesenchymal tumours.

HAS AP-225



APPROVED

France



Avapritinib

Population:
Adult
30 June 2023

Monotherapy for
treatment of aggressive
systemic mastocytosis,
systemic mastocytosis
associated with a
haematological
neoplasm, or mast cell
leukaemia.

HAS AP-216



APPROVED

Pharmacological Technologies



Cancer


Germany



Zanubrutinib

Population:
Adult

15 June 2023



Treatment of patients previously untreated for chronic lymphocytic leukaemia.

IQWiG A22-130




Germany



Zanubrutinib

Population:
Adult

15 June 2023




Treatment of patients previously untreated for chronic lymphocytic leukaemia.

IQWiG A23-41




Brazil



Rituximab

Population:
Unknown

29 June 2023




Chemotherapy with fludarabine and cyclophosphamide for the first-line treatment of chronic lymphocytic leukemia.

CONITEC




England



Daratumumab with bortezomib and dexamethasone


Population:
Adult

06 June 2023



An option for previously treated multiple multiple myeloma

NICE TA897



Under special arrangement

Pharmacological Technologies



Cancer

England




Axicabtagene ciloleucel

Population:
Adult

07 June 2023

For treating relapsed or refractory diffuse large B-cell lymphoma after firstline chemoimmunotherapy

NICE TA895

 **APPROVED**

Under special arrangement

England



Axicabtagene ciloleucel

Population:
Adult

07 June 2023

For treating relapsed or refractory follicular lymphoma after 3 or more systemic treatments in adults.

NICE TA894

 **NOT APPROVED**

England




Brexucabtagene autoleucel

Population:
Adult
For adults 26 and older

07 June 2023


For treating relapsed or refractory B-cell acute lymphoblastic leukaemia

NICE TA893

 **APPROVED**

Under special arrangement

England




Dabrafenib plus trametinib

Population:
Adult

14 June 2023

for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

NICE TA898

 **APPROVED**

Under special arrangement


Pharmacological Technologies



Cancer

<p>England</p>  <p>Cemiplimab</p> <p>Population: Adult</p> <p>20 June 2023</p>	<p>For treating recurrent or metastatic cervical cancer</p> <p><i>NICE TA901</i></p> <p>TERMINATED</p> <p>Submission terminated</p>	<p>England</p>  <p>Pembrolizumab with lenvatinib</p> <p>Population: Adult</p> <p>21 June 2023</p>	<p>For previously treated advanced or recurrent endometrial cancer</p> <p><i>NICE TA904</i></p> <p>APPROVED</p> <p>Under special arrangements</p>
<p>England</p>  <p>Darolutamide with androgen deprivation therapy and docetaxel</p> <p>Population: Adult</p> <p>21 June 2023</p>	<p>For treating hormone-sensitive metastatic prostate cancer</p> <p><i>NICE TA903</i></p> <p>APPROVED</p> <p>Under special arrangement</p>	<p>Wales</p>  <p>Cemiplimab</p> <p>Population: Adult</p> <p>21 June 2023</p>	<p>As monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy</p> <p><i>AWMSG 4189</i></p> <p>EXCLUDED</p> <p>Due to NICE appraisal TA901</p>

Pharmacological Technologies



Cardiovascular

Germany



Dapagliflozin

Population:
Adult

01 June 2023

Treatment of symptomatic chronic heart failure with left ventricular ejection fraction lower than 40%.

IQWiG A23-11



Brazil



Rituximab

Population:
Unknown

29 June 2023

For remission therapy in newly diagnosed and cases of relapsed vasculitis associated with anti-neutrophil cytoplasmic antibodies, granulomatosis with polyangiitis.

CONITEC



Switzerland



Direct oral anticoagulants

Population:
Unknown

07 June 2023

Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation.

FOPH



England



Dapagliflozin

Population:
Adult

21 June 2023


For treating chronic heart failure with preserved or mildly reduced ejection fraction

NICE TA902



Under special arrangements

Pharmacological Technologies



Cardiovascular



Endocrine

Wales



Mavacamten

Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults

AWMSG 4028



Due to NICE appraisal ID3928

Scotland



Metreleptin

Population:
Other Adult and Children, 2 year and above

12 June 2023

Supplementary to diet as a replacement therapy to treat complications of leptin deficiency in lipodystrophy patients.

SMC2559



Ultra-orphan initial assessment

Brazil



Liraglutide

Population:
Unknown

29 June 2023

Treatment of patients with obesity, pre-diabetes, and high risk of cardiovascular disease.

CONITEC



Pharmacological Technologies



Eye

France



Inebilizumab

Monotherapy treatment for patients with neuromyelitis optic spectrum disorders.

HAS AP-197



Population:
Adult

01 June 2023

Germany



Latanoprost/
netarsudil

Treatment for primary open-angle glaucoma or ocular hypertension in patients that do not benefit from prostaglandin or netarsudil monotherapy.

IQWiG A23-39



Population:
Adult

15 June 2023

Addendum to IQWiG A22-129

Germany



Latanoprost/
netarsudil

Treatment for primary open-angle glaucoma or ocular hypertension in patients that do not benefit from prostaglandin or netarsudil monotherapy.


IQWiG A22-129



Population:
Adult


15 June 2023

Pharmacological Technologies



Gastrointestinal


Scotland



Upadacitinib


Population:
Adult

12 June 2023



Treatment of moderately to severely active Crohn's disease.

SMC2575




Germany



Risankizumab


Population:
Adult

15 June 2023



Treatment for moderately to severely active Crohn's disease.

IQWiG A23-40




Germany



Risankizumab


Population:
Adult

15 June 2023



Treatment for moderately to severely active Crohn's disease.

IQWiG A22-133




England



Bulevirtide

Population:
Adult

07 June 2023




For treating chronic hepatitis D in adults with compensated liver disease

NICE TA896



Under special arrangement

Pharmacological Technologies



Gastrointestinal

England



Upadacitinib

Population:
Adult

21 June 2023

For previously treated moderately to severely active Crohn's disease

NICE TA905



Under special arrangements

Wales



Upadacitinib

Population:
Adult

21 June 2023

Treatment of adult patients with moderate to severe active Crohn's disease (CD) who have had an inadequate response or intolerance to one or more conventional and/or biologic therapies

AWMSG 4252



Due to NICE appraisal TA905


Pharmacological Technologies



Genitourinary

<p>Germany</p>  <p>Voclosporin</p> <p>Population: Adult</p> <p>01 June 2023</p>	<p>Treatment for patients with lupus nephritis.</p> <p><i>IQWiG A23-16</i></p> <p>NOT APPROVED</p>	<p>Germany</p>  <p>Finerenone</p> <p>Population: Adult</p> <p>01 June 2023</p>	<p>Treatment of chronic kidney disease associated with type 2 diabetes mellitus.</p> <p><i>IQWiG A23-15</i></p> <p>NOT APPROVED</p>
<p>Germany</p>  <p>Finerenone</p> <p>Population: Adult</p> <p>01 June 2023</p>	<p>Treatment of chronic kidney disease associated with type 2 diabetes mellitus.</p> <p><i>IQWiG A23-14</i></p> <p>NOT APPROVED</p>	<p>England</p>  <p>Botulinum toxin type A</p> <p>Population: Unknown</p> <p>28 June 2023</p>	<p>Injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention</p> <p><i>NICE IPG766</i></p> <p>APPROVED</p> <p>Under special arrangements</p>

Pharmacological Technologies



Infection

<p>Scotland</p>  <p>Tixagevimab and cilgavimab</p> <p>Population: Unknown</p> <p>14 June 2023</p>	 <p>Pre-exposure prophylaxis of COVID-19 who are not infected or been recently exposed.</p> <p><i>SMC2580</i></p> <p> NOT APPROVED</p>	<p>Germany</p>  <p>Dolutegravir/abacavir/lamivudine</p> <p>Population: Children Age 2 to 12 years</p> <p>01 June 2023</p>	 <p>Treatment for children with HIV-1 infection.</p> <p><i>IQWiG A23-17</i></p> <p> NOT APPROVED</p>
<p>England</p>  <p>Tixagevimab plus cilgavimab</p> <p>Population: Adult</p> <p>14 June 2023</p>	 <p>For preventing COVID-19</p> <p><i>NICE TA900</i></p> <p> NOT APPROVED</p>	<p>England</p>  <p>Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab</p> <p>Population: Adult</p> <p>22 June 2023</p>	 <p>For treating COVID-19</p> <p><i>NICE TA878</i></p> <p> APPROVED</p> <p>Under special arrangement</p>

Pharmacological Technologies



Mental Health



Metabolic/Genetic

Germany



Esketamine

For patients with treatment-resistant major depressive disorder.

IQWiG A23-18



Population:
Adult

15 June 2023

France



Evinacumab

Treatment of patients suffering from homozygous familial hypercholesterolemia.

HAS AP-215



Population:
Other Adults and adolescents above 12 years
21 June 2023

England



Esketamine

For treating major depressive disorder in adults at imminent risk of suicide

NICE TA899




Population:
Adult


06 June 2023

Submission terminated

Pharmacological Technologies



Musculoskeletal



Skin

Canada



Alternative therapies to Immunoglobulin

Population: Unknown

29 June 2023

Alternative Therapies to Immunoglobulin for Idiopathic Inflammatory Myopathies

CADTH RC1484-000



England



Deucravacitinib

Population: Adult

28 June 2023

For treating moderate to severe plaque psoriasis

NICE TA907



Under special arrangement

Wales



Deucravacitinib

Population: Unknown

05 June 2023

Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy

AWMSG 4071



Due to NICE appraisal TA907

Pharmacological Technologies

Other

Germany



Olopatadine/
mometasone

Population:
Other
Adult and
adolescents, over 12
years
01 June 2023



Treatment of moderate
to severe nasal
symptoms associated
with allergic rhinitis.


IQWiG A22-125



Non-pharmacological Technologies



Cancer



Gastrointestinal

Brazil



Photodynamic
therapy

Population:
Unknown

28 June 2023

Treatment of non-melanoma skin cancer of the superficial and nodular basal cell carcinoma type.

CONITEC



England



Endoscopic
ultrasound

Population:
Unknown

22 June 2023


Guided gallbladder drainage for acute cholecystitis when surgery is not an option

NICE IPG764



Under special
arrangements

Non-pharmacological Technologies



Musculoskeletal



Neurology

England



Minimally invasive fusionless posterior-approach surgery

Population:
Children
Children and young people

22 June 2023

Surgery to correct idiopathic scoliosis

NICE IPG765



Should be used only in research

Canada



Deep brain stimulation

Population:
Unknown

13 June 2023

Deep brain stimulation involves the surgical insertion of electrodes to stimulate targeted areas of the brain to help control symptoms of Parkinson disease.

CADTH HC0065-000



England



Radiofrequency denervation

Population:
Unknown

28 June 2023

For osteoarthritic knee pain

NICE IPG767



Under special arrangements

Non-pharmacological Technologies



Respiratory

Spain



Telemonitoring of
lung function

Population:
Other
Adult and children

09 June 2023



Monitoring lung
function through self-
administered spirometry
in patients with asthma,
COPD or cystic fibrosis.

AQuAS



Diagnostic Tests



Blood



Cancer

Switzerland



Folic acid test

Population:
Unknown

23 June 2023

Testing for folic acid deficiency.

FOPH



England



Transperineal biopsy

Population:
Unknown


01 June 2023

Local anaesthetic transperineal (LATP) prostate biopsy using the freehand needle positioning device PrecisionPoint for diagnosing prostate cancer.

NICE DG54



Diagnostic Tests



Cardiovascular

Germany




Computer tomography coronary angiography

Population: Unknown

28 June 2023

For diagnosis in patients with suspected chronic coronary artery disease.

IQWiG D22-01



Gastrointestinal

England



FibroScan

Population: Unknown

07 June 2023

Assessing liver fibrosis or cirrhosis outside secondary and specialist care

NICE DG48



Under special arrangement

Diagnostic Tests



Infection


Spain



Nucleotide
amplification in
blood

Population:
Unknown

22 June 2023



Molecular techniques of nucleotide amplification in blood applied to the rapid etiological diagnosis of sepsis.

AQuAS



Other Guidance



Cancer


Switzerland



Tisagenlecleucel/
axicabtagene
ciloleucel

Population:
Unknown

16 June 2023

The CAR T cell 
therapies
tisagenlecleucel and
axicabtagene ciloleucel
for the treatment of B
cell acute lymphoblastic
leukaemia, diffuse large
B cell lymphoma and
primary mediastinal B
cell lymphoma
FOPH



Norway



177Lu-PSMA-617

Population:
Unknown

02 June 2023

Treatment of metastatic
castration resistant
prostate cancer
NIPH



England



Intraoperative
electron beam
radiotherapy

Population:
Unknown

06 June 2023

Radiotherapy for locally
advanced and locally
recurrent colorectal
cancer
NICE IPG763



Other Guidance



Neurology


Ireland



Domiciliary invasive ventilation

Population:
Unknown

06 June 2023

Management of spinal cord injuries 

HIQA



Pregnancy


United States



Postpartum care

Population:
Unknown


02 June 2023

Postpartum Care up to 1 Year After Pregnancy: A Systematic Review and Meta-Analysis 

AHRQ



Other Guidance



Skin


Canada



Antimicrobial or
antiseptic cleansers

Population:
Other
Adults and children

28 June 2023

 Review of chronic
wound care, assessing
antiseptics and
antimicrobials

CADTH RC1488-000



About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

REVIEWS

Systematic Literature Reviews
Global Value Dossiers
Narrative Reviews
Rapid Reviews
Targeted Reviews

HEALTH ECONOMICS

Return on Investment
Network Meta-Analysis
Budgetary Impact Analysis
Cost-effectiveness Analysis

ACTUARIAL

Risk Management
Pricing & Reserving

MODELLING

Mortality and Morbidity Modelling
Synthetic Sample Generation
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

Registered address

17 High Street,
Stanford-le-Hope,
Essex, SS17 0HD
+44 (0)1375 517878

Company No: 7980921

Data Protection Act Registration Number: Z3363643

Websites:

www.crystallise.com

www.heoro.com

www.evidencemapper.co.uk